Equities

Deltex Medical Group PLC

DEMG:LSE

Deltex Medical Group PLC

Actions
Health CareMedical Equipment and Services
  • Price (GBX)0.09
  • Today's Change0.00 / 0.00%
  • Shares traded251.23k
  • 1 Year change-40.00%
  • Beta0.8518
Data delayed at least 20 minutes, as of Nov 08 2024 15:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Deltex Medical Group Plc is a United Kingdom-based medical device company. The Company develops, manufactures and distributes a hemodynamic monitoring technology. The Company's TrueVue platform offers three monitoring technologies, such as Oesophageal Doppler Monitoring (ODM+), Pulse Pressure Waveform Analysis (PPWA) and High Definition Impedance CardioGraphy (HD-ICG). Its ODM+ is a fluid management and cardiac output monitoring technology to directly measure both flow and pressure in adults and pediatrics. HD-ICG provides continuous and sensitive measurements of cardiac output and other hemodynamic parameters. The system is stabilized using HD-Z signal filter technology. HD-ICG disposable electrodes are placed on the neck and chest. PPWA uses the researched pulse pressure wave algorithm, which is available to derive hemodynamic parameters, calibrated from the Doppler. Its applications include surgery, acute kidney injury, enhanced recovery, paediatric, and COVID-19 critical care.

  • Revenue in GBP (TTM)1.78m
  • Net income in GBP-1.29m
  • Incorporated2000
  • Employees37.00
  • Location
    Deltex Medical Group PLCTerminus RoadCHICHESTER PO19 8TXUnited KingdomGBR
  • Phone+44 124 377 4837
  • Fax+44 124 353 2534
  • Websitehttps://www.deltexmedical.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Truspine Technologies PLC0.00-560.51k841.65k1.00--0.3013-----0.0047-0.00470.000.01830.00-------14.76-18.95-19.81-23.20-----------14.490.1455------14.35---0.7314--
Deltex Medical Group plc1.78m-1.29m1.71m37.00--0.5862--0.9581-0.0007-0.00070.0010.00150.31560.91135.2348,135.14-22.92-14.66-35.89-21.8162.2171.84-72.60-32.930.4855-3.310.4245---28.44-18.55-11.97--9.78--
Feedback plc1.18m-3.30m2.60m24.00--0.3401--2.20-0.2474-0.24740.08860.57330.1178--7.70---32.88-28.12-35.63-30.7293.3091.80-279.16-312.58--------15.2715.98-13.03--26.72--
Image Scan Holdings Plc2.56m-11.06k3.90m14.00--2.8042.321.52-0.00008-0.000080.01870.01021.072.385.38183,209.30-0.4626-1.15-0.7257-1.7750.5751.36-0.4312-1.011.69--0.00--47.98-3.08145.65--40.19--
Surgical Innovations Group Plc12.54m-622.00k5.13m101.00--0.513263.340.4092-0.0007-0.00070.01340.01070.85252.605.48124,148.50-4.23-8.19-5.38-9.9428.8532.51-4.96-13.310.8677-3.510.1225--5.941.84-292.80--7.20--
Aptamer Group PLC860.00k-2.96m5.28m38.00--1.45--6.14-0.0075-0.00750.00210.00190.31153.783.0322,631.58-107.14---227.63--29.07---343.95--1.17-54.110.4795---50.91--62.25------
Myhealthchecked PLC9.39m-1.04m6.50m10.00--0.8627--0.692-0.0201-0.02010.1810.14491.035.1726.92939,400.00-11.41-7.24-12.91-10.397.9222.82-11.06-5.1311.58--0.0016---50.81368.95-110.48---2.00--
Rua Life Sciences PLC2.19m-1.44m6.67m33.00--0.9289--3.04-0.0551-0.05510.06530.11570.31684.303.9166,393.94-20.82-24.63-22.39-26.8181.06---65.72-97.078.81-23.340.0514--0.550736.4628.11--122.88--
Genincode PLC2.60m-5.94m7.34m36.00--2.61--2.83-0.0507-0.05070.01930.01590.441116.953.4872,194.45-100.88---127.83--49.44---228.70--2.55--0.0849--51.05---26.21------
Cambridge Nutritional Sciences PLC9.77m-328.00k7.61m94.00--0.786523.650.779-0.0015-0.00150.04110.04070.69085.394.62103,978.70-2.32-11.43-2.60-12.9861.8658.79-3.36-26.725.03--0.0151--29.532.2289.66---53.43--
Proteome Sciences plc4.04m-4.08m7.97m35.00------1.98-0.0138-0.01380.0137-0.01780.39274.694.61115,285.70-39.69-1.22----2.1154.53-101.07-2.200.1388-3.701.63---35.3710.52-284.38--126.22--
Verici DX PLC3.35m-3.72m8.23m19.00--1.08--2.45-0.0204-0.02040.01710.03150.4038--5.71239,531.30-44.82---58.12--77.06---110.99------0.0183------23.43------
Data as of Nov 08 2024. Currency figures normalised to Deltex Medical Group PLC's reporting currency: UK Pound GBX

Institutional shareholders

16.17%Per cent of shares held by top holders
HolderShares% Held
Herald Investment Management Ltd.as of 25 Jan 2024107.69m5.68%
Janus Henderson Investors UK Ltd.as of 12 Feb 201932.47m1.71%
Evelyn Partners Investment Management LLPas of 01 Oct 202424.73m1.30%
Pilling & Co. Stockbrokers Ltd.as of 01 Oct 202424.24m1.28%
Interactive Investor Services Ltd.as of 12 Feb 201921.68m1.14%
Hargreaves Lansdown Asset Management Ltd.as of 12 Feb 201921.53m1.14%
T. Rowe Price International Ltd.as of 04 Apr 202419.72m1.04%
Barclays Bank Plc (Private Banking)as of 12 Feb 201919.41m1.02%
J.O. Hambro Capital Management Ltd.as of 26 Jul 201818.60m0.98%
Jarvis Investment Management Ltd.as of 12 Feb 201916.50m0.87%
More ▼
Data from 30 Jun 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.